Comparative Study of Intact Parathyroid Hormone, Calcium, Phosphate And Radiological Changes In Patients With End Stage Renal Disease On Maintenance Haemodialysis And Newly Diagnosed End Stage Renal Disease
Summary: Secondary hyperparathyroidism and renal bone disease are invariable consequences of chronic kidney disease. Calcitriol deficiency, hypocalcemia and hyperphosphatemia are responsible for raised parathyroid hormone and renal bone disease in both pre-dialysis and maintenance dialysis patients....
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Technical Report |
| Language: | en_US |
| Published: |
NATIONAL ACADEMY OF MEDICAL SCIENCES
2013
|
| Online Access: | http://103.69.126.140:8080/handle/123456789/398 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Summary: Secondary hyperparathyroidism and renal bone disease are invariable consequences of chronic kidney disease. Calcitriol deficiency, hypocalcemia and hyperphosphatemia are responsible for raised parathyroid hormone and renal bone disease in both pre-dialysis and maintenance dialysis patients. Calcitriol therapy and control of serum phosphate with protein restricted diet and phosphate binders result in correction of hyperparathyroidism and reversion of the renal bone histology.
Since the initiation of nephrology service in Nepal, these therapies are practiced in all chronic kidney disease patients without any studies on the severity of hyperparathyroidism, renal bone disease and the beneficial and adverse effects of these drugs. So this study was carried out to initiate the study on renal bone disease and to see the degree of hyperparathyroidism, hypocalcemia, hyperphophatemia and the radiological changes in Nepalese patients with end stage renal disease on maintenance haemodialysis (ESRD on MHD) and newly diagnosed end stage renal disease (NESRD) and to evaluate the beneficial effect of haemodialysis on secondary hyperparathyroidism.
Twenty three (16 male, 7 female) ESRD on MHD patients with twice a week dialysis for 6 to 78 (22 +3, mean +SEM) months with protein restricted diet and calcium acetate as a phosphate binder but without calcitriol therapy and twenty three ( 16 male, 7 female) NERSD patients without protein restricted diet, phosphate binder and calcitriol therapy were included in this study and fasting blood samples were collected for estimation of serum intact parathyroid hormone (PTH), calcium, phosphate and alkaline phosphatase and all were subjected to X-ray hands A/P view and X-ray lumbosacral spine lateral view. |
|---|